Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triticum vulgare aqueous extract is a hydrosoluble complex derived from the common wheat plant, specifically obtained from germinated whole plants using standardized procedures[1][5]. The extract is rich in oligosaccharides and other bioactive compounds, and it is primarily used for its wound-healing and tissue-regenerative properties in dermatology and skin care[1][5]. The mechanism of action includes stimulating fibroblast proliferation, enhancing actin polymerization, increasing synthesis of extracellular matrix components like fibronectin and hyaluronan, promoting lipid synthesis in keratinocytes, and reducing the expression of inflammatory mediators such as IL-6, TNFα, prostaglandin E2, and nitric oxide[1][5]. The extract modulates multiple phases of the wound healing process, including inflammation, cell proliferation, and tissue remodeling. It is marketed for topical use in management of skin ulcers, burns, superficial wounds, and minor skin irritations[2][3][4][5]. Clinical studies support its anti-inflammatory effects, capacity to accelerate wound closure, and role in improving skin barrier function[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on triticum vulgare aqueous extract.